<SEC-DOCUMENT>0001193805-19-000540.txt : 20190529
<SEC-HEADER>0001193805-19-000540.hdr.sgml : 20190529
<ACCEPTANCE-DATETIME>20190529071525
ACCESSION NUMBER:		0001193805-19-000540
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20190529
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20190529
DATE AS OF CHANGE:		20190529

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ADMA BIOLOGICS, INC.
		CENTRAL INDEX KEY:			0001368514
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				562590442
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36728
		FILM NUMBER:		19859799

	BUSINESS ADDRESS:	
		STREET 1:		C/O ADMA BIOLOGICS, INC.
		STREET 2:		465 STATE ROUTE 17
		CITY:			RAMSEY
		STATE:			NJ
		ZIP:			07446
		BUSINESS PHONE:		(201) 478-5552

	MAIL ADDRESS:	
		STREET 1:		C/O ADMA BIOLOGICS, INC.
		STREET 2:		465 STATE ROUTE 17
		CITY:			RAMSEY
		STATE:			NJ
		ZIP:			07446

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	R&R ACQUISITION VI, INC
		DATE OF NAME CHANGE:	20060707
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>e618494_8k-adma.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CURRENT REPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Date of Report (Date of earliest event reported):
<U>May 29, 2019</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="3" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font: 18pt Times New Roman, Times, Serif"><B>ADMA BIOLOGICS, INC.</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="3" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Exact name of registrant as specified in its charter)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center; width: 30%">&nbsp;</TD>
    <TD STYLE="text-align: center; width: 30%">&nbsp;</TD>
    <TD STYLE="text-align: center; width: 30%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Delaware</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-36728</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">56-2590442</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(State or other jurisdiction</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">of incorporation)&nbsp;</P></TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Commission</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">File Number)</P></TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(IRS Employer</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Identification No.)</P></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">465 State Route 17, Ramsey, New Jersey </FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">07446</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address of principal executive offices)</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Zip Code)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Registrant&rsquo;s telephone number, including
area code: <U>(201) 478-5552</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 100%; border-bottom: black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Former name or former address, if changed since last report.)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (<I>see</I> General Instruction
A.2. below):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Wingdings">o</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif">Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Wingdings">&uml;</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif">Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Wingdings">&uml;</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif">Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Wingdings">&uml;</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif">Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Securities registered pursuant to Section 12(b) of the Act:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 30%; border: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title of each class</FONT></TD>
    <TD STYLE="width: 30%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trading Symbol(s)</FONT></TD>
    <TD STYLE="width: 30%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name of each exchange on which registered</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common Stock</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ADMA</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nasdaq Capital Market</FONT></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Indicate by check mark whether the registrant
is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (&sect;230.405 of this chapter)
or Rule 12b-2 of the Securities Exchange Act of 1934 (&sect;240.12b-2 of this chapter).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Emerging
growth company&nbsp;</FONT><FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&nbsp;</FONT><FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"><B>Item 8.01</B></TD><TD><B>Other Events.</B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Adam Grossman, the President and Chief Executive Officer of
ADMA Biologics, Inc., a Delaware corporation (the &ldquo;Company&rdquo;), and Brian Lenz, the Company&rsquo;s Executive Vice President
and Chief Financial Officer, are scheduled to present a corporate overview at the following conferences in June 2019:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 22.5pt">&bull;</TD><TD>Jefferies 2019 Healthcare Conference at the Grand Hyatt in New York, NY, on Thursday, June 6, 2019 at 9:00 AM ET.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 22.5pt">&bull;</TD><TD>Raymond James Life Sciences and MedTech Conference at the Lotte New York Palace, New York, NY, on Wednesday, June 19, 2019
at 10:20 AM ET.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">These presentations will be webcast live and may be accessed
under the &ldquo;Investor Relations&rdquo; tab on the Company's website at www.admabiologics.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Please refer to Exhibit 99.1 for a discussion of certain forward-looking
statements included therein and the risk and uncertainties related thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 96px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item 9.01</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Financial Statements and Exhibits.</B></FONT></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(d) Exhibits</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 96px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Exhibit No.</U></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Description</U></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="e618494_ex99-1.htm" STYLE="-sec-extract: exhibit">Press Release of the Company, dated May 29, 2019.</A></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>SIGNATURE</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 29, 2019</FONT></TD>
    <TD COLSPAN="3"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ADMA Biologics, Inc.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Brian Lenz</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&nbsp;</FONT></TD>
    <TD STYLE="width: 25%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Brian Lenz</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Executive Vice President and Chief Financial Officer</FONT></TD></TR>
</TABLE>


<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>e618494_ex99-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0"><IMG SRC="image001.jpg" ALT="">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ADMA Biologics to Present at Upcoming
Investor Conferences</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>Jefferies 2019 Healthcare Conference
</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>Raymond James Life Sciences and MedTech
Conference </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">RAMSEY, N.J. and BOCA RATON, FL., &ndash; May 29, 2019 &ndash;
ADMA Biologics, Inc. (NASDAQ: ADMA) (&ldquo;ADMA&rdquo; or the &ldquo;Company&rdquo;), a vertically integrated commercial biopharmaceutical
and specialty immunoglobulin company that manufactures, markets and develops specialty plasma-derived biologics for the treatment
of immune deficiencies and the prevention of certain infectious diseases, announces that President and Chief Executive Officer,
Adam Grossman and Executive Vice President and Chief Financial Officer, Brian Lenz are scheduled to present a corporate overview
at the following conferences in June 2019:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Jefferies 2019 Healthcare Conference at the Grand Hyatt in New York, NY, on Thursday, June 6, 2019 at 9:00 AM ET.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Raymond James Life Sciences and MedTech Conference at the Lotte New York Palace, New York, NY, on Wednesday, June 19, 2019
at 10:20 AM ET.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">A webcast of the live presentation will be available on the
Company's website at https://ir.admabiologics.com/events-webcasts and will be archived for 90 days following the event.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>About
ADMA Biologics, Inc. (ADMA)</B></FONT><BR>
ADMA Biologics is a vertically integrated biopharmaceutical manufacturer with three FDA approved commercial specialty plasma-based
biologics. ADMA's mission is to develop and commercialize plasma-derived, human immune globulins targeted to niche patient populations
for the treatment and prevention of certain infectious diseases and management of immune compromised patient populations. The target
patient populations include immune compromised individuals who suffer from an underlying immune deficiency disease, or who may
be immune compromised for other medical reasons. ADMA has received U.S. Patents 9,107,906, 9,714,283, 9,815,886, 9,969,793 and
10,259,865 related to certain aspects of its products and product candidates. For more information, please visit www.admabiologics.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About Primary Immune Deficiency Disease (&ldquo;PI&rdquo;)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">PI is a class of inherited genetic disorders that causes an
individual to have a deficient or absent immune system. According to the World Health Organization, there are approximately 350
different genetic mutations encompassing PI. Some disorders present at birth or in early childhood, the disorders can affect anyone
regardless of age or gender. Some affect a single part of the immune system, others may affect one or more components of the system.
PI patients are vulnerable to infections and more likely to suffer complications from these infections as compared to individuals
with a normal functioning immune system. The infections may occur in any part of the body. Because patients suffering from PI lack
a properly functioning immune system, they typically receive monthly treatment with polyclonal immune globulin products. Without
this exogenous antibody replacement, these patients would remain vulnerable to persistent and chronic infections. PI has an estimated
prevalence of 1:1,200 in the United States, or approximately 250,000 people in the U.S.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About ASCENIV&trade; (Formerly referred to as RI-002)</B><BR>
ASCENIV&trade;, Immune Globulin Intravenous, Human &ndash; slra 10% Liquid, is a plasma-derived, polyclonal, intravenous immune
globulin (&ldquo;IVIG&rdquo;). &nbsp;ASCENIV&trade; is protected by U.S. Patents: 9,107,906, 9,714,283 and 9,815,886.&nbsp; ASCENIV&trade;
is manufactured using our unique, patented plasma donor screening methodology and tailored plasma pooling design, which blends
normal source plasma and plasma from donors tested using our proprietary microneutralization assay.&nbsp; ASCENIV&trade; contains
naturally occurring polyclonal antibodies.&nbsp; ASCENIV&trade; is indicated for the treatment of Primary Humoral Immunodeficiency
(&ldquo;PI&rdquo;) in adults and adolescents (12 to 17 years of age). &nbsp;ADMA received FDA approval for ASCENIV&trade; on April
1, 2019. Polyclonal antibodies are proteins that are used by the body's immune system to neutralize microbes, such as bacteria
and viruses and prevent against infection and disease. &nbsp;ASCENIV&trade; prevented serious bacterial infection among fifty-nine
patients treated for twelve months during the pivotal investigation.&nbsp; The most common adverse reactions to ASCENIV&trade;
(<FONT STYLE="font-family: Times New Roman, Times, Serif">&ge;</FONT>5% of study subjects) were headache, sinusitis, diarrhea,
gastroenteritis viral, nasopharyngitis, upper respiratory tract infection, bronchitis, and nausea. &nbsp;ADMA anticipates the commercial
launch of ASCENIV&trade; during the second half of 2019.&nbsp; Certain data and other information about ASCENIV&trade; or ADMA
Biologics and its products can be found on the Company&rsquo;s website at:&nbsp;<FONT>www.admabiologics.com</FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About BIVIGAM&reg;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">BIVIGAM&reg; is an immune globulin intravenous (human), 10%
liquid, indicated for the treatment of primary humoral immunodeficiency. This includes, but is not limited to, X-linked and congenital
agammaglobulinemia, common variable immunodeficiency, Wiskott-Aldrich syndrome and severe combined immunodeficiency. These PIs
are a group of genetic disorders. Initially thought to be very rare, it is now believed that as many as 250,000 people in the U.S.
have some form of PI. BIVIGAM&reg; contains a broad range of antibodies similar to those found in normal human plasma. These antibodies
are directed against bacteria and viruses, and help to protect PI patients against serious infections. BIVIGAM&reg; is a purified,
sterile, ready-to-use preparation of concentrated human Immunoglobulin (&ldquo;IgG&rdquo;) antibodies. Antibodies are proteins
in the human immune system that work to defend against infections and disease. FDA&rsquo;s initial approval for BIVIGAM&reg; was
received by BPC in December 2012, and production of BIVIGAM&reg; was halted by BPC in December 2016. ADMA obtained ownership and
all rights, title and interest in BIVIGAM&reg; in June 2017 as part of the Biotest Therapy Business Unit (&ldquo;BTBU&rdquo;) asset
acquisition and resumed the production of BIVIGAM&reg; during the fourth quarter of 2017. Using ADMA&rsquo;s optimized IVIG manufacturing
process, FDA approved a PAS to amend the BLA for the product on May 9, 2019 allowing the Company to resume the supply of drug to
the U.S. market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About Nabi-HB&reg;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Nabi-HB&reg;&nbsp;is a hyperimmune globulin that is rich in
antibodies to the Hepatitis B virus. Nabi-HB&reg; is a purified human polyclonal antibody product collected from plasma donors
who have been previously vaccinated with a Hepatitis B vaccine. Nabi-HB&reg; is indicated for the treatment of acute exposure to
blood containing Hepatitis B surface antigen (&ldquo;HBsAg&rdquo;), prenatal exposure to infants born to HBsAg-positive mothers,
sexual exposure to HBsAg-positive persons and household exposure to persons with acute Hepatitis B virus infection. Hepatitis B
is a potentially life-threatening liver infection caused by the Hepatitis B virus. It is a major global health problem and can
cause chronic infection and put people at high risk of death from cirrhosis and liver cancer. Nabi-HB&reg;&nbsp;has a well-documented
record of long-term safety and effectiveness since its initial market introduction. FDA approval for Nabi-HB&reg; was received
on March 24, 1999. Biotest acquired Nabi-HB&reg; from Nabi Biopharmaceuticals in 2007. ADMA resumed production of Nabi-HB&reg;
in the third quarter of 2017, as substantially all of the Nabi-HB&reg; inventory received as part of the Biotest Transaction has
been sold in the normal course of business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Cautionary Note Regarding Forward-Looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>This press release contains &quot;forward-looking statements&quot;
pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, about ADMA Biologics, Inc. (&quot;we&ldquo;,
&ldquo;our&rdquo; or the &ldquo;Company&rdquo;). Forward-looking statements include, without limitation, any statement that may
predict, forecast, indicate, or imply future results, performance or achievements, and may contain the words &quot;estimate,&quot;
&ldquo;project,&rdquo; &quot;intend,&quot; &ldquo;forecast,&rdquo; &quot;target,&rdquo; &rdquo;anticipate,&rdquo; &ldquo;plan,&rdquo;
&ldquo;planning,&rdquo; &ldquo;expect,&rdquo; &ldquo;believe,&rdquo; &ldquo;will,&quot; &ldquo;is likely,&rdquo; &ldquo;will likely,&rdquo;
&ldquo;should,&rdquo; &ldquo;could,&rdquo; &quot;would,&quot; &quot;may,&quot; or, in each case, their negative, or words or expressions
of similar meaning. These forward-looking statements also include, but are not limited to, statements concerning our plans to develop,
manufacture, market, launch and expand our own commercial infrastructure and commercialize our current products and future products,
the safety, efficacy and expected timing of, and our ability to, obtain and maintain regulatory approvals of our current products,
product expansions into new fields of use, indications and product candidates, and the labeling or nature of any such approvals,
our ability to successfully pursue commercialization and prelaunch activities for our products, the potential of our specialty
plasma-based biologics products and product candidates to provide meaningful clinical improvement for patients living with Primary
Immune Deficiency Disease or other indications, our ability to realize increased prices for plasma growth in the plasma collection
industry and our expectations for future capital requirements. Actual events or results may differ materially from those described
in this document due to a number of important factors. Current and prospective security holders are cautioned that there also can
be no assurance that the forward-looking statements included in this press release will prove to be accurate. In light of the significant
uncertainties inherent in the forward-looking statements included herein, the inclusion of such information should not be regarded
as a representation or warranty by ADMA or any other person that the objectives and plans of ADMA will be achieved in any specified
time frame, if at all. Except to the extent required by applicable laws or rules, ADMA does not undertake any obligation to update
any forward-looking statements or to announce revisions to any of the forward-looking statements. Forward-looking statements are
subject to many risks, uncertainties and other factors that could cause our actual results, and the timing of certain events, to
differ materially from any future results expressed or implied by the forward-looking statements, including, but not limited to,
the risks and uncertainties described in our filings with the U.S. Securities and Exchange Commission, including our most recent
reports on Form 10-K, 10-Q and 8-K, and any amendments thereto.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">COMPANY CONTACT:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Brian Lenz</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Executive Vice President and Chief Financial Officer | 201-478-5552
| www.admabiologics.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">INVESTOR RELATIONS CONTACT:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Jeremy Feffer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Managing Director, LifeSci Advisors, LLC | 212-915-2568 |</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0 B17AI9@  34T *@    @  0$2  ,
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MU]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$! 0$! 0
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MS7W;^P'_ ,$D]%_:7^!4/C+QIJ_B#2?[6G<Z7!ILD,8:W7Y?,<R1/DLX; &
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M&?\ X-Y__BJ/^&U_B[_T4GQG_P"#>?\ ^*K]$/\ APM\+_\ H:/'W_@7:?\
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M+#DDVE>G%/1V>ECPN(7Q!DN-E@,;B)J<4F[3;6JNM;GIQ_;5^+A_YJ1XS_\
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M>UHI.,5N[JSUM9*]GV=C]N\%:.>YAF3QL\1/V$/BNVU)O:-G==;M]#TPC(%
MX-9HU@C77LI(]G[L2PN,XD'1ATQD<<9Z,*TBV*_DFCB*=5/D?PMI]+-?UIY'
M]9.+6XZBBBN@D_(G_@NC_P GCZ7_ -BM;?\ I5=U\9-]ZOLW_@NC_P GCZ7_
M -BM;?\ I5=U\9[2[X )).  .2:_O[PL:7"F#;_D_5G\">)2;XHQ:7\_^1ZY
M^Q%^R]??M:?M Z5X9A3_ (E<+B]UF?+ 0VB,N\9 X=\A%Z<MU&"1^RW[1/QD
MT?\ 9'_9RUCQ$UO##9^';$0V-G& JR28$<$*C@ %B@]AGTKR7_@E!^R)'^S9
M^S[;ZQJ5G);^+O&4<=[J(F0K+:Q<F& J?NE5;+# .YR#]T5[5\=?V>/!?[2O
MAZVT?QMI?]M:;9W NHK?[9-;JLH4J&/E.NX@,P&<XR?6OYE\2>-,-G?$<(UG
M*6$H2Y;1LW)7]YJ[2]YJR=]DF?TIX<\'8G)>'95*/+'%5XWO*]EI[J>E]+W:
MMN>:_P#!.?\ ;0A_;#^"L=S?30+XOT,+:ZU;IM7<^.)U0'B.3!QP,,KCH!7P
MW_P6<_9(7X/?&&'X@:1$?[$\<3/]M3C%K?@ G' XE7+]2=RR=.*_1#X$?L8_
M#']F;Q!=:KX(\/KHNH7UO]EGD74;B998]RM@I)*RYRHP<9'/."<Z'[6?[.]C
M^U+\!->\'WCQP/J$&ZSNGCW_ &2X0[HI0.O# 9P02I89YKR^'>+\%DG%*S'+
M%*&%F[.,DKJ,M]$W\+U6M]+'I\0<(XS.N&'@,R<9XJ"O&46[.2VW2U:T?F?D
MW_P2-/\ QL"\"_[M_P#^D,]?JO\ MQ?$S6O@[^RCXU\3>';M;+6M'L#/:3F)
M)!$^Y1G:X*G@GJ#7Y>?\$QO!VH_#?_@IGX9T'5X&M=4T:XU2RNHF_@DCL[A6
MYZ$9'!'!&#7ZE?MI_";5_CC^R_XP\)Z$MNVL:U8FWM1/)Y<9?<I^9L' P#7V
M/B_B,+5XQP5:JTZ,H4FV[.+C[25[]+6WZ6/D?"2CB:?".-HTDU54ZB25TU+D
MC:W5._XGY2_\/>OV@/\ H=K?_P $UG_\:JWH/_!8KX\:1K5I=77B:QU.UMYE
MDFLYM*MHX[E <F-F2-74$<94@BM,_P#!%3XX _\ 'GX9_P#!J?\ XBKWAC_@
MB+\8M6UVVM]2D\,Z38RMB>\^VM<&!<=1&J@L>P&1R>2!S7ZCB,5X:>QEIA]N
MD8W^5E>_IKV/S'#X7Q%]M&SQ&_5RM\[NUO70_72WG_M/14D9<>?"&(],KTKY
M;_X)&:%:^%_@KXYTNQC\JSTSQWJUI;QEBVR.-HT49/)P .3S7U)! NF:(L;-
MN^SP[2?H/_K5\L_\$A?$%OXN^!_C;5[/<UGJGCG5;R N-K&.1HW7(['!'%?R
MG@^;^Q\9R?#STO2_OV_"_P")_46,M_;."Y_CY*GK:T+_ (GKGA?]I.TU+]J_
MQ/\ #"\,$%]INEVFKZ<>C7<4F]9EP>I1@AX[2=/E)KXO_P""YG[+OERZ/\6-
M)MY.B:5KFQ,J@Y^SS-Z<DQDGCF,<'KP/_!3KXOZO\!/^"FNG>+-#FDBO]%TZ
MPG")(8Q<H&DWPN1U1URI'3!Z5^B5K<>$?VZ/V7FVL;WPSXVTUHV."LD)/!ZX
M(>-Q_P!]+7WF%P^(X2KY9Q-AT_8UH1YTN[24U\U[T?-/L?#XG$4.+*.8\-8A
MKVU*3<&^U[Q?R?NOR?F?*_\ P1"_9=_X0OX<:E\3-4MY$U#Q0#9Z8)$P4LD<
M%G'?][(OXB)2,@U]C>&?C/I?BSXR^)O!=DRS7_A6RLKJ_=7R(FNC-LC([,$A
M#]>DB\>O,_'?XL>&?V'OV9[K5/LZ6^E^&[%++2[%2?W\@79!"#@GYB "QS@9
M8]#7R)_P0S\;:E\2?B-\:->UJZDO=6U=],NKF:1BS,[->'J23@< #L !VKS<
MVPV*XCH9CQ;BDU"#BH+S<HQ2_P"W8[^;3[GI93BL-P[7R[A3#-.I)-S?DHMM
M_.6WDC9_X+[<?!KP'_V')/\ T0]?G]^RG^SKJO[4_P <M%\'Z6K*+Q_-OK@9
MVV=JA!ED) ." <+GJ[(,\U^@/_!?<X^#G@3_ +#<G_HAZ[3_ ((]?L?)\#O@
MC_PF6LV<L/BOQD@E*S(R265D#F&+:>A;'F$X!^91_#D_I7#?&$>'_#R-:#_>
MU)3C!>;;U]$M?N74_-^(N$99_P"(,J$E^ZA&$IOR26GJWH?2'B36O#?[+OP,
MNKQDATGPUX/TPLL:'"QQ1)A47N6.  .2Q(ZDUX1_P2]_;JG_ &O/"?B2RUYK
M>'Q+HNH2W(A5CE[.>1GBV@DDB,DQ''0+'G&X9^@?C'\(/#/QX\#7'AKQ;9C4
M]%NW22:V^U26_F%&#+EHV5L @'&<''-<3\$?V'/A3^SGXQ;Q!X,\-KHVJM;M
M:M.NI7,H>-B"5*22,IY4=1D8XK\/PF,REY3B*>,C.6*G).$DDXJV]VVG[UW?
M1]&?MF*PN:K-</4P4X1PM.+4HMM-W[))K2RMJNI\,?\ !;3]DA?!'CBS^*>C
MQM]A\23+9ZQ&,;8;H)^ZD  Z2(A!R3\R#^]7P0*_H*_:*^"NF_M$_!;Q!X.U
M3:MKKEJT(EV!S;R#YHY0.[(X5AR/N]17X+_%GX8:I\%?B7K7A76HQ'J>@W;V
ML^W[LFT\.O\ LLN&'LPK^H/ WC+^T<L>4XF5ZM#;NX=/_ =O2W<_F?QLX/\
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M .S=XTD\3^!!!<;C-IK>268_?';\N1^%%<'^R+>R#Q+JD(B+1S0*[R#HK*V
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M2LH63VZPZ=&?-87B:E2Q.$K2@VJ--P:O:]W*[6_277JCO3^QI\6O^B9^./\
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MC_P-MO\ Y'H_X<5?"7_H->./_ VV_P#D>BBC_B(G$O\ T&U/_ F'_$.>&O\
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)W'4445U$G__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
